Patents by Inventor Anthony Futerman

Anthony Futerman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190151424
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 23, 2019
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
  • Patent number: 10265412
    Abstract: The present invention relates in general to the field of enzyme replacement therapy, and specifically to chimeric proteins including protein hormone-therapeutic protein conjugates and fusion proteins, wherein the protein hormone is selected from a protein hormone which is able to cross the blood brain barrier, for the treatment of lysosomal storage diseases, compositions of the same and to methods of use thereof.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: April 23, 2019
    Assignees: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science, The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Naftali Stern, Ruth Navon, Anthony Futerman, Ari Zimran, Etty Osher
  • Patent number: 10159724
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: December 25, 2018
    Assignees: Icahn School of Medicine at Mount Sinai, Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
  • Publication number: 20170273917
    Abstract: The present invention provides pharmaceutical compositions comprising at least one NMDA receptor antagonist for use in treating neuropathic forms of Gaucher Disease (nGD).
    Type: Application
    Filed: September 10, 2015
    Publication date: September 28, 2017
    Inventors: Anthony FUTERMAN, Andres David KLEIN
  • Publication number: 20170030926
    Abstract: A biomarker of the neuronopathic types of Gaucher's disease (nGD) is provided, and use thereof for assisting the diagnosis of this form of the disease and its severity. In particular, use of the level of trans-membrane glycoprotein non-metastatic B (GPNMB) or a fragment thereof in the cerebrospinal fluid (CSF) as a diagnostic marker of nGD is provided. Further provided are methods for selecting drugs and assessing the efficacy of drugs and therapies for treating nGD.
    Type: Application
    Filed: August 11, 2016
    Publication date: February 2, 2017
    Inventors: Anthony FUTERMAN, Hila Zigdon
  • Publication number: 20170020998
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
  • Patent number: 9492514
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: November 15, 2016
    Assignees: Icahn School of Medicine at Mount Sinai, Universitaet Duisberg-Essen, Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
  • Publication number: 20160051629
    Abstract: The present invention provides compositions and methods for treating lysosomal storage disease characterized by elevation of RIP kinase in a subject in need thereof using at least one RIP kinase inhibitor.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 25, 2016
    Inventors: Anthony FUTERMAN, Einat VITNER, Ran SALOMON
  • Publication number: 20150258043
    Abstract: Methods of preventing or treating bacterial infections, including but not limited to Pseudomonas aeruginosa infections, by administering sphingoid long chain bases (LCB) are provided. The invention further relates to the use of sphingoid long chain bases, or pharmaceutical composition comprising same, for the treatment of lung diseases or disorders such as cystic fibrosis and chronic obstructive pulmonary disease.
    Type: Application
    Filed: October 15, 2013
    Publication date: September 17, 2015
    Inventors: Anthony Futerman, Yael Pewzner-Jung, Erich Gulbins
  • Publication number: 20150125439
    Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 7, 2015
    Applicant: Universitatsstrasse 2
    Inventors: Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
  • Patent number: 7855063
    Abstract: A method of identifying a compound capable of correcting an impaired enzymatic activity of a mutant glucocerebrosidase molecule, the method comprising: (a) obtaining a first set of structure coordinates, the first set of structure coordinates defining a 3D structure of a glucocerebrosidase molecule capable of displaying normal enzymatic activity or a portion thereof; (b) computationally generating using the first set of structure coordinates a second set of structure coordinates, the second set of structure coordinates defining a predicted 3D structure of the mutant glucocerebrosidase molecule or a portion thereof; and (c) computationally identifying, using the second set of structure coordinates, a compound capable of interacting with the mutant glucocerebrosidase molecule in such a way as to correct the impaired enzymatic activity thereof, thereby identifying the compound capable of correcting the impaired enzymatic activity of the mutant glucocerebrosidase molecule.
    Type: Grant
    Filed: April 18, 2004
    Date of Patent: December 21, 2010
    Assignee: Yeda Research And Development Co. Ltd.
    Inventors: Anthony Futerman, Joel L. Sussman, Israel Silman, Michal Harel, Hay Dvir, Lilly Toker
  • Publication number: 20100183577
    Abstract: The present invention relates in general to the field of enzyme replacement therapy, and specifically to chimeric proteins including protein hormone-therapeutic protein conjugates and fusion proteins, wherein the protein hormone is selected from a protein hormone which is able to cross the blood brain barrier, for the treatment of lysosomal storage diseases, compositions of the same and to methods of use thereof.
    Type: Application
    Filed: February 6, 2007
    Publication date: July 22, 2010
    Inventors: Naftali Stern, Ruth Navon, Anthony Futerman, Ari Zimran, Etty Osher
  • Publication number: 20070166813
    Abstract: A method of identifying a compound capable of correcting an impaired enzymatic activity of a mutant glucocerebrosidase molecule, the method comprising: (a) obtaining a first set of structure coordinates, the first set of structure coordinates defining a 3D structure of a glucocerebrosidase molecule capable of displaying normal enzymatic activity or a portion thereof; (b) computationally generating using the first set of structure coordinates a second set of structure coordinates, the second set of structure coordinates defining a predicted 3D structure of the mutant glucocerebrosidase molecule or a portion thereof; and (c) computationally identifying, using the second set of structure coordinates, a compound capable of interacting with the mutant glucocerebrosidase molecule in such a way as to correct the impaired enzymatic activity thereof, thereby identifying the compound capable of correcting the impaired enzymatic activity of the mutant glucocerebrosidase molecule.
    Type: Application
    Filed: April 18, 2004
    Publication date: July 19, 2007
    Inventors: Anthony Futerman, Joel Sussman, Israel Silman, Michal Harel, Hay Dvir, Lilly Toker, Swetlana Adamsky